1. Home
  2. CHY vs FTRE Comparison

CHY vs FTRE Comparison

Compare CHY & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Convertible and High Income Fund

CHY

Calamos Convertible and High Income Fund

HOLD

Current Price

$12.10

Market Cap

896.9M

Sector

Finance

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$13.71

Market Cap

829.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHY
FTRE
Founded
2003
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
896.9M
829.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
CHY
FTRE
Price
$12.10
$13.71
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$14.06
AVG Volume (30 Days)
218.2K
1.5M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
10.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$10.20
$3.97
52 Week High
$13.11
$18.67

Technical Indicators

Market Signals
Indicator
CHY
FTRE
Relative Strength Index (RSI) 42.32 60.60
Support Level $11.24 $8.85
Resistance Level $13.11 $18.26
Average True Range (ATR) 0.24 0.84
MACD -0.09 -0.08
Stochastic Oscillator 8.70 57.55

Price Performance

Historical Comparison
CHY
FTRE

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: